• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Eli Lilly and Company

    5/9/25 4:12:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SD 1 formsd2025.htm SD Document





    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ________________

    FORM SD
    Specialized Disclosure Report
    ________________


    ELI LILLY AND COMPANY
    (Exact name of registrant as specified in its charter)





    Indiana
    001-06351
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    Lilly Corporate Center Indianapolis, Indiana
    (Address of principal
    executive offices)
    Jonathan Groff (317-450-5089)
    (Name and telephone number, including area code, of the person to contact in connection with this report)



    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in the form applies:

    ý Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024

    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ____


    Section 1 – Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure and Report
    The Conflict Minerals Report for Eli Lilly and Company (the “Company) for the year ended December 31, 2024 is attached as Exhibit 1.01 to this Report and is available on the Company’s website at https://investor.lilly.com/financial-information/sec-filings.




    Item 1.02 Exhibit
    Exhibit No.Description
    1.01
    Conflict Minerals Report of Eli Lilly and Company for the year ended December 31, 2024.





    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    ELI LILLY AND COMPANY
    (Registrant)
    By:/s/ Lucas MontarceDated: May 9, 2025
    Name:Lucas Montarce
    Title:Executive Vice President and Chief Financial Officer




    Get the next $LLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings